BACKGROUND: Chemokines and their receptors are known to play important roles in the tumorigenesis of many malignancies. The aim of this study was to evaluate the prognostic impact of the expression of the chemokine receptors CXCR4 and CXCR7 in patients with pancreatic adenocarcinoma (PAC). METHODS: Expression of CXCR4 and CXCR7 in specimens from 249 patients with PAC was evaluated by immunohistochemistry on a tissue microarray and matched with clinicopathological parameters and overall survival. RESULTS: Expression of CXCR4 was detected in 215 patients (86.4%) and CXCR7 in 47 patients (18.9%). No association between CXCR4 and CXCR7 expression was evident, although all the CXCR7 positive tumors were also CXCR4 positive. pT1/2 tumors showed a higher frequency of CXCR7 expression than pT3/4 tumors (P = 0.018), while more dedifferentiated tumors had elevated CXCR7 expression (P = 0.036). Overall and disease-free survival revealed no association with either CXCR4 or CXCR7 expression. CONCLUSION: CXCR7 is associated with tumor grade and inversely associated with tumor size and may play a potential role in tumor progression and differentiation. In contrast to previously reported data our results revealed no significant association between CXCR4 expression and clinical or pathological data.
BACKGROUND: Chemokines and their receptors are known to play important roles in the tumorigenesis of many malignancies. The aim of this study was to evaluate the prognostic impact of the expression of the chemokine receptors CXCR4 and CXCR7 in patients with pancreatic adenocarcinoma (PAC). METHODS: Expression of CXCR4 and CXCR7 in specimens from 249 patients with PAC was evaluated by immunohistochemistry on a tissue microarray and matched with clinicopathological parameters and overall survival. RESULTS: Expression of CXCR4 was detected in 215 patients (86.4%) and CXCR7 in 47 patients (18.9%). No association between CXCR4 and CXCR7 expression was evident, although all the CXCR7 positive tumors were also CXCR4 positive. pT1/2tumors showed a higher frequency of CXCR7 expression than pT3/4tumors (P = 0.018), while more dedifferentiated tumors had elevated CXCR7 expression (P = 0.036). Overall and disease-free survival revealed no association with either CXCR4 or CXCR7 expression. CONCLUSION:CXCR7 is associated with tumor grade and inversely associated with tumor size and may play a potential role in tumor progression and differentiation. In contrast to previously reported data our results revealed no significant association between CXCR4 expression and clinical or pathological data.
Authors: Stephan Kruger; Michael Haas; Steffen Ormanns; Sibylle Bächmann; Jens T Siveke; Thomas Kirchner; Volker Heinemann; Stefan Boeck Journal: World J Gastroenterol Date: 2014-08-21 Impact factor: 5.742
Authors: Theodore S Hong; David P Ryan; Darrell R Borger; Lawrence S Blaszkowsky; Beow Y Yeap; Marek Ancukiewicz; Vikram Deshpande; Shweta Shinagare; Jennifer Y Wo; Yves Boucher; Raymond C Wadlow; Eunice L Kwak; Jill N Allen; Jeffrey W Clark; Andrew X Zhu; Cristina R Ferrone; Harvey J Mamon; Judith Adams; Barbara Winrich; Tarin Grillo; Rakesh K Jain; Thomas F DeLaney; Carlos Fernandez-del Castillo; Dan G Duda Journal: Int J Radiat Oncol Biol Phys Date: 2014-05-24 Impact factor: 7.038
Authors: Ihsan Ekin Demir; Kristina Kujundzic; Paulo L Pfitzinger; Ömer Cemil Saricaoglu; Steffen Teller; Timo Kehl; Carmen Mota Reyes; Linda S Ertl; Zhenhua Miao; Thomas J Schall; Elke Tieftrunk; Bernhard Haller; Kalliope Nina Diakopoulos; Magdalena U Kurkowski; Marina Lesina; Achim Krüger; Hana Algül; Helmut Friess; Güralp O Ceyhan Journal: Proc Natl Acad Sci U S A Date: 2016-12-16 Impact factor: 11.205